The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1323
October 19, 2009
View Complete Issue         Table of Contents 2019 
Degarelix (Firmagon) for Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Degarelix (Firmagon) for Prostate Cancer
October 19, 2009 (Issue: 1323)
The FDA has approved degarelix (Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer. Abarelix (Plenaxis), the first GnRH antagonist...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Degarelix (Firmagon) for Prostate Cancer
Article code: 1323b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.